Clinical trial
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
NCT00064350 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00064350 |
|---|---|
| Title | Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer |
| Official title | A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Sorafenib, Placebo |
| Enrollment | 342 |
| Start date | Jun 28, 2004 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Jul 9, 2003 |
| Last update posted | Jun 29, 2023 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: